Valuation: Syndax Pharmaceuticals, Inc.

Market Cap 1.2B 1.07B 986M 895M 1.68B 114B 1.7B 11.87B 4.7B 59.46B 4.49B 4.39B 188B P/E 2026 *
-6.63x
P/E 2027 * -16x
Enterprise Value 1.55B 1.38B 1.28B 1.16B 2.17B 147B 2.21B 15.39B 6.09B 77.08B 5.82B 5.7B 243B EV / Sales 2026 *
4.94x
EV / Sales 2027 * 3.38x
Free-Float
98.31%
Yield 2026 *
-
Yield 2027 * -
1 day-1.25%
1 week-1.83%
Current month-28.72%
1 month-26.31%
3 months-39.23%
6 months-39.31%
Current year-36.22%
1 week 12.8
Extreme 12.795
13.61
1 month 12.8
Extreme 12.795
18.94
Current year 12.8
Extreme 12.795
25.59
1 year 12.8
Extreme 12.795
25.59
3 years 8.58
Extreme 8.58
25.59
5 years 8.58
Extreme 8.58
29.86
10 years 3.39
Extreme 3.39
29.86
Manager TitleAgeSince
Chief Executive Officer 55 2022-02-02
Chief Tech/Sci/R&D Officer 57 2013-10-31
Director of Finance/CFO 55 2022-06-12
Director TitleAgeSince
Chairman 68 2008-11-30
Director/Board Member 55 2019-07-03
Director/Board Member 65 2017-01-03
Date Insider Type Main position Quantity % Market Cap. Importance
7/8/26 Exercice

Chief Executive Officer

97,125 0.1096%
6/1/26 Sell

Chief Financial Officer

-1,177 0.0013%
6/1/26 Sell

Chief Executive Officer

-6,847 0.0077%
Change 5-day change 1-year change 3-year change Capi.($)
-1.25%-1.83%-11.32%+16.42% 1.17B
+2.41%-6.33%+43.43%+71.02% 63.29B
-0.15%+3.11%+10.29%+72.56% 54.89B
+0.57%+4.64%+12.82%+89.79% 53.28B
+0.37%+3.07%+28.23%+51.53% 45.81B
-1.21%+0.95%+20.44%+128.58% 43.46B
-0.37%-1.20%+252.94%+568.54% 40.23B
+0.05%+6.75%+14.48%+56.75% 33.45B
+1.19%-5.84%+27.86%-0.65% 23.7B
-0.38%+4.55%+37.71%+28.10% 23.76B
Average +0.12%+0.23%+43.69%+108.26% 38.31B
Weighted average by Cap. +0.37%+0.55%+47.99%+121.79%

Financials

2026 *2027 *
Net sales 314M 280M 259M 235M 440M 29.82B 447M 3.12B 1.23B 15.61B 1.18B 1.15B 49.26B 459M 410M 378M 343M 643M 43.58B 653M 4.56B 1.8B 22.81B 1.72B 1.69B 72B
Net income -180M -161M -148M -135M -252M -17.09B -256M -1.79B -707M -8.94B -675M -661M -28.22B -77.54M -69.22M -63.9M -57.98M -109M -7.36B -110M -769M -304M -3.85B -291M -285M -12.16B
Net Debt 355M 317M 292M 265M 497M 33.67B 504M 3.52B 1.39B 17.62B 1.33B 1.3B 55.62B 356M 318M 293M 266M 498M 33.76B 506M 3.53B 1.4B 17.67B 1.33B 1.31B 55.78B
Projected Income Statement - Annual - Syndax Pharmaceuticals, Inc.
Logo Syndax Pharmaceuticals, Inc.
Syndax Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company. It is focused on developing a pipeline of cancer therapies. Its product candidates include Revuforj and Niktimvo. It is developing Revuforj, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged also known as mixed lineage leukemia rearranged, acute leukemias including acute lymphoblastic leukemia and acute myeloid leukemia (AML), and necleophosmin 1, also known as NPM1, mutant AML. It is also exploring the use of Revuforj as a treatment in solid tumors, specifically its activity in metastatic colorectal cancer. It is also developing Niktimvo, a monoclonal antibody that blocks the colony stimulating factor 1 receptor (CSF-1R) in chronic graft-versus-host disease (cGVHD), as well as idiopathic pulmonary fibrosis. Entinostat is its oral, small molecule product candidate that has direct effects on both cancer cells and immune regulatory cells.
Employees
298
Date Price Change Volume
26-10-23 US$13.40 -1.25% 4,246,400
26-10-22 US$13.57 +3.19% 2,362,751
26-10-21 US$13.15 -0.75% 2,587,704
26-10-20 US$13.25 +1.22% 3,912,542
26-10-19 US$13.09 +1.47% 2,192,507
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BB
MarketScreener Ratings - Syndax Pharmaceuticals, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
12
Last Close Price
13.57USD
Average target price
37.27USD
Spread / Average Target
+174.67%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Syndax Pharmaceuticals, Inc.
  1. Stock Market
  2. Stocks
  3. SNDX Stock